Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
tRNA (uracil-5-)-methyltransferase homolog B (TRMT2B)
- Target
- TRMT2B
- Molecular classification
- Enzyme, RNA methyltransferase, tRNA/rRNA-modifying enzyme, S-adenosyl-L-methionine-dependent methyltransferase
01
Overview
tRNA (uracil-5-)-methyltransferase homolog B (TRMT2B) is a nuclear-encoded, S-adenosyl-L-methionine-dependent methyltransferase that localizes to mitochondria, where it catalyzes the formation of 5-methyluridine at specific positions (U54 in mitochondrial tRNAs and U429 in mitochondrial 12S rRNA). This modification is important for tRNA maturation and may influence mitochondrial translation. Inactivation of TRMT2B impairs the activity of mitochondrial respiratory chain complexes I, III, and IV via effects on proteins synthesized in mitochondria, though it does not impact overall RNA stability or translation under standard cellular conditions. Variants in TRMT2B have been associated with juvenile ALS and neuromuscular diseases, implicating the enzyme in mitochondrial function and disease pathology.
- Other names
- CXorf34FLJ12687dJ341D10.3TRM2 homolog BrRNA (uracil-5-)-methyltransferase TRMT2BtRNA (uracil(54)-C(5))-methyltransferase homologDJ341D10.3
02
Mechanism of action
Not applicable (no known drugs target TRMT2B directly as of now). Mechanism would likely involve inhibition or modulation of methyltransferase activity.
03
Biological functions
RNA methylation (formation of 5-methyluridine)tRNA maturation (methylates uridine at position 54 in mitochondrial tRNAs)rRNA modification (methylates uridine at position 429 in mitochondrial 12S rRNA)Proper mitochondrial RNA processing and translation
04
Disease associations
Neuromuscular diseaseJuvenile amyotrophic lateral sclerosis (ALS) (certain TRMT2B variants are associated)Mitochondrial dysfunction (impairs complexes I, III, IV activity when disrupted)
05
Safety considerations
Disruption of TRMT2B activity leads to impaired mitochondrial respiratory chain complex function, highlighting potential risks for mitochondrial toxicity and neuromuscular pathologies if targeted therapeutically
06
Biomarkers
TRMT2B gene variants (may serve as genetic biomarkers in ALS and neuromuscular disease contexts)m^5U54 modification status in mt-tRNAsm^5U429 modification status in 12S rRNA
Beyond the preview
Go deeper on tRNA (uracil-5-)-methyltransferase homolog B (TRMT2B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tRNA (uracil-5-)-methyltransferase homolog B (TRMT2B).